News: Medicine

View:

2004

 

Found press releases

 

COMPANIES ACT 1985 SECTION 198

12/27/2004 2:00 AM EST  -   AstraZeneca
DISCLOSURE OF INTEREST IN VOTING SHARES IN PUBLIC COMPANIES
On 24 December 2004 we were informed by The Capital Group Companies, Inc., a registered investment manager in the U.S., that on 22 December 2004 its interest in the USD0.25 Ordinary Shares of AstraZeneca PLC had decreased to 233,153,407 shares (14.16 per cent of the current issued ordinary capital) from the previously notified level of 244,411,808...

Micronic and ASML sign a license agreement for optical maskless lithography

12/21/2004 3:00 AM EST  -   Micronic
Taby, Sweden – December 21, 2004 – Micronic Laser Systems AB and ASML Netherlands B.V. in the Netherlands have today signed a license agreement that gives ASML the right to market optical maskless lithography for semiconductor applications based on Micronic’s patent portfolio in the SLM (Spatial Light Modulator) technology and datapath.
- The license agreement gives ASML exclusive rights to use Micronic’s...

CLINICAL AND REGULATORY CHANGES AT ASTRAZENECA- GUIDANCE FROM SIR TOM McKILLOP, ...

12/17/2004 6:07 AM EST  -   AstraZeneca
AstraZeneca is committed to the development of innovative medicines but Exanta and Iressa, two products based on breakthrough science, have suffered setbacks.

Following the non-approval of Exanta by FDA, we accelerated a significant programme of change in the development and regulatory functions, based on the learning from these and other experiences. Today’s announcement of John Patterson’s appointment to the...

ASTRAZENECA BOARD ANNOUNCEMENT

12/17/2004 6:06 AM EST  -   AstraZeneca
AstraZeneca PLC today confirms the appointment of Louis Schweitzer as non-executive Chairman with effect from 1 January 2005. Percy Barnevik will retire from the Board as Chairman and a Director on 31 December 2004. The appointment of Louis Schweitzer as Chairman was anticipated in the announcement of his appointment as a non-executive Director on 11 March 2004.

The Company also announces the appointment to the...

GEFITINIB (IRESSA™) LUNG CANCER ISEL TRIAL SHOWS NO OVERALL SURVIVAL ADVANTAGE I...

12/17/2004 6:05 AM EST  -   AstraZeneca
AstraZeneca today announced that the initial analysis of the primary endpoint of Study 709, IRESSA Survival Evaluation in Lung cancer (ISEL) with 1692 patients has been conducted, and shows that IRESSA failed to significantly prolong survival in comparison to placebo in the overall population (HR 0.89, p=0.11, Median 5.6 vs 5.1 months), or in patients with adenocarcinoma (HR 0.83, p=0.07, Median 6.3 vs 5.4 months)....

ELEKTA'S BOARD DECIDES ON REPURCHASE OF OWN SHARES

12/14/2004 7:02 AM EST  -   Elekta
PRESS RELEASE
Stockholm, December 14, 2004

The Board of Directors of Elekta has decided to utilize the authorization the Board received from the Annual General Meeting to repurchase shares in the company.
Elekta’s dividend policy is to distribute 20 percent or more of net profits to shareholders in the form of dividends, share repurchases or comparable measures.

Based on this policy, the company’s strong...

Elekta - Interim report for the six-month period May 1 – October 31, 2004/05

12/14/2004 7:00 AM EST  -   Elekta
• Profit after tax rose by 43 percent to SEK 114 M (80). Earnings per share increased to SEK 3.65 (2.45) before dilution and SEK 3.65 (2.42) after dilution.

• Operating profit rose by 55 percent to SEK 166 M (107) and the operating margin increased to 11 percent (8). Operating profit for the second quarter improved to SEK 91 M (54).

• Cash flow after investments was negative in an amount of SEK 10 M (positive:...

MAXIM PHARMACEUTICALS REPORTS FISCAL 2004 FINANCIAL RESULTS

12/13/2004 3:05 AM EST  -   Maxim Pharmaceuticals
SAN DIEGO, Calif., December 13, 2004 -- Maxim Pharmaceuticals, Inc. (NASDAQ NM: MAXM, SSE: MAXM) today reported financial results for the fourth quarter and the year ended September 30, 2004. The net loss applicable to common stock for the fourth quarter ended September 30, 2004 totaled $14.5 million, or $0.51 per share, compared to a net loss applicable to common stock of $12.8 million, or $0.54 per share, for the...

MYRIAD GENETICS FILES IND FOR DRUG CANDIDATE FROM COMPOUND FAMILY LICENSED FROM ...

12/9/2004 7:00 AM EST  -   Maxim Pharmaceuticals
SAN DIEGO, Calif., December 9, 2004 -- Maxim Pharmaceuticals, Inc. (NASDAQ: MAXM, SSE: MAXM) today reported that Myriad Genetics, Inc., filed an Investigational New Drug (IND) application with the FDA for a Phase 1 clinical study of MPC-6827, a pro-apoptotic cancer therapeutic candidate identified by Myriad researchers from a family of compounds licensed from Maxim. The study is designed to evaluate the safety and...

Maxim Pharmaceuticals Reports Data from its Phase 3 Trial of Ceplene in Acute My...

12/6/2004 2:35 PM EST  -   Maxim Pharmaceuticals
SAN DIEGO, December 6, 2004 – Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM) announced today additional data from its randomized and controlled Phase 3 trial (MP-MA-0201) investigating Ceplene plus Interleukin-2 (IL-2) in the treatment of acute myeloid leukemia (AML) patients in complete remission during an oral presentation at the American Society of Hematology 46th Annual Meeting and Exposition. The data...